Ann: Strategic Partnership and Lead Program, page-10

Certainly some interesting aspects below. First seems to be an ever increasing closeness to Sarepta? We now have someone officially involved in the company who has their name on Sarepta branded products currently in market. Surely at the very least Sarepta will be following to see of the tech is of use and maybe even spill over into dmd which was our earlier target wasnt it?
Also interesting they refer to LEI "co investment" in the new entity. Is that maybe just the supply of staff and labs or is there actually a mc and shares on ussue for the new venture? As others asked, what are the details, finances, terms?

PYC has also formalised our relationship with Professor Sue Fletcher, a global leader in the design
of ASOs for rare diseases. Prof. Fletcher will join PYC on a part-time basis as Chief of Research and
Development to support both our Retinitis Pigmentosa program and build our pipeline of CPP-ASO
drugs. Prof. Fletcher is the inventor of Eteplirsen, marketed as Exondys 51 by Sarepta Therapeutics,
a world’s first treatment for Duchenne Muscular Dystropthy generating ~$500million AUD in sales
over the last 12 months.
Professor Fletcher’s appointment gives PYC and Vision the ability to create proprietary drug
molecules to couple with our delivery platform. The product of this design and delivery capability
is a pipeline of RNA therapeutics set to fulfil the promise of precision medicine. LEI's co-investment
in Vision gives PYC the ability to take drug molecules through the entire development cycle or
from ‘bench to bedside’. The Ocular Tissue Engineering Laboratory at LEI has expertise spanning
both pre-clinical and clinical drug development and evaluation.